Eli Lilly (LLY) came out with quarterly earnings of $6.31 per share, beating the Zacks Consensus Estimate of $5.61 per share. This compares to earnings of $3.92 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.48%. A quarter ago, it was expected that this drugmaker would post earnings of $3.52 per share when it actually produced earnings of $3.34, delivering a surprise of -5.11%.Over the last four quarters, the company has ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a ...

Pfizer (PFE) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +34.48%. A quarter ago, it was expected that this drugmaker would post earnings of $0.64 per share when it actually produced earnings of $0.92, delivering a surprise of +43.75%.Over the last four quarters, the company has sur ...

Company Overview - Eli Lilly (LLY) closed at $762.95, reflecting a -5.59% change from the previous day, which is worse than the S&P 500's daily loss of 0.3% [1] - Over the last month, Eli Lilly's shares increased by 3.67%, outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The upcoming earnings report for Eli Lilly is expected on August 7, 2025, with an anticipated EPS of $5.61, representing a 43.11% increase year-over-year [2] - Revenue is forecasted to be $14.75 billion, indicating a 30.49% growth compared to the same quarter of the previous year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $22.05 per share and revenue of $60.55 billion, reflecting increases of +69.75% and +34.43% respectively from the prior year [3] - Recent changes to analyst estimates for Eli Lilly are noted as indicators of optimism regarding the business outlook [3] Stock Performance and Valuation - The Zacks Rank system, which assesses estimate changes, indicates that Eli Lilly currently holds a Zacks Rank of 3 (Hold) [5] - The Zacks Consensus EPS estimate has increased by 0.48% in the past month [5] - Eli Lilly's Forward P/E ratio is 36.64, which is a premium compared to its industry's Forward P/E of 14.23 [5] Industry Context - Eli Lilly operates within the Large Cap Pharmaceuticals industry, which has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [7] - The average PEG ratio for the Large Cap Pharmaceuticals industry is 1.24, while Eli Lilly's PEG ratio is 1.15 [6]

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.97%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.15 per share when it actually produced earnings of $2.22, delivering a surprise of +3.26%.Over the last four quarters, the comp ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that mea ...

Company Performance - AbbVie (ABBV) closed at $190.58, marking a +2.25% move from the prior day, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, AbbVie shares appreciated by 0.49%, while the Medical sector experienced a loss of 3.4% [1] Upcoming Earnings - AbbVie is expected to release its earnings report on July 31, 2025, with analysts forecasting earnings of $3.02 per share, indicating a year-over-year growth of 13.96% [2] - The consensus estimate anticipates revenue of $15.04 billion, reflecting a 3.97% increase from the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $12.07 per share and revenue of $60.12 billion, representing shifts of +19.27% and +6.72% respectively from the previous year [3] - Recent changes in analyst estimates suggest a favorable outlook on AbbVie's business health and profitability [3] Valuation Metrics - AbbVie is currently trading at a Forward P/E ratio of 15.44, which is a premium compared to the industry average of 14.02 [6] - The company has a PEG ratio of 1.23, aligning with the average PEG ratio of the Large Cap Pharmaceuticals industry [7] Industry Ranking - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Group 1 - Johnson & Johnson reported quarterly earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, but down from $2.82 per share a year ago, representing an earnings surprise of +4.14% [1] - The company achieved revenues of $23.74 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.13% and increasing from $22.45 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 7.3% since the beginning of the year, outperforming the S&P 500's gain of 6.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.75 on revenues of $23.17 billion, and for the current fiscal year, it is $10.64 on revenues of $91.33 billion [7] Group 3 - The Zacks Industry Rank indicates that the Large Cap Pharmaceuticals sector is in the top 26% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this category [8] - Johnson & Johnson currently holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.14%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.57 per share when it actually produced earnings of $2.77, delivering a surprise of +7.78%.Ov ...

Core Viewpoint - Strong Q2 results from banks and financial firms highlight the importance of monitoring upcoming earnings reports from medical companies, which can serve as a hedge against market volatility [1][2]. Group 1: Johnson & Johnson (JNJ) - Johnson & Johnson is a leader in the Zacks Large Cap Pharmaceuticals Industry, which ranks in the top 29% of over 240 Zacks industries [3]. - The company is expected to report Q2 results on July 16, with EPS projected to dip 5% to $2.66, but shares trade at a reasonable forward earnings multiple of 14.7X [4]. - JNJ has a 3.32% annual dividend yield, above the industry average of 2.57% and the S&P 500's 1.18% [4]. - The bottom line is projected to expand 6% this year, with FY26 EPS forecasted to rise 4% to $11.09 per share [5]. - The Most Accurate estimate for Q2 EPS is $2.72, which is 2% above the Zacks Consensus [5][6]. Group 2: Novartis (NVS) - Novartis is also part of the top-rated Zacks Large Cap Pharmaceuticals Industry and will report Q2 results on July 17 [6]. - Q2 sales are expected to rise 9% year-over-year to $14.04 billion, with EPS projected to increase 21% to $2.38 [8]. - FY25 EPS estimates have slightly increased, with FY26 EPS estimates rising from $9.14 to $9.35 per share [8]. - NVS trades at an attractive forward earnings multiple of 13.5X and offers a 2.14% annual dividend yield [8]. Group 3: Abbott Laboratories (ABT) - Abbott Laboratories will report Q2 results on July 17, with a diversified line of healthcare products [10]. - Q2 earnings are expected to rise 9% to $1.25 per share, with the Most Accurate estimate at $1.27, slightly above the Zacks Consensus [10][12]. - Sales for Q2 are projected to increase nearly 7% to $11.07 billion, with mid to high single-digit growth expected for the annual outlook [10]. - ABT has a forward earnings multiple of 25.6X, near the industry average, and a 1.79% annual dividend yield [11]. Conclusion - The outlook for Johnson & Johnson, Novartis, and Abbott Laboratories suggests these stocks are worthy of consideration, especially in the context of potential market volatility [13].